tiprankstipranks
Trending News
More News >
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
US Market

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Compare
2,163 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$178.00
▲(62.01%Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $178.00 with a high forecast of $210.00 and a low forecast of $148.00. The average price target represents a 62.01% change from the last price of $109.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","211":"$211","106.75":"$106.8","141.5":"$141.5","176.25":"$176.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$210.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":178,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$178.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,106.75,141.5,176.25,211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,115.53230769230768,123.40461538461538,131.27692307692308,139.14923076923077,147.02153846153846,154.89384615384614,162.76615384615383,170.63846153846154,178.51076923076923,186.3830769230769,194.25538461538463,202.1276923076923,{"y":210,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,113.07076923076923,118.48153846153846,123.8923076923077,129.30307692307693,134.71384615384616,140.12461538461537,145.5353846153846,150.94615384615383,156.35692307692307,161.7676923076923,167.17846153846153,172.58923076923077,{"y":178,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,110.76307692307692,113.86615384615385,116.96923076923076,120.07230769230769,123.17538461538462,126.27846153846154,129.38153846153847,132.48461538461538,135.5876923076923,138.69076923076923,141.79384615384615,144.8969230769231,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$210.00Average Price Target$178.00Lowest Price Target$148.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AXSM
TipRanks AITipRanks
Not Ranked
TipRanks
$113
Hold
2.85%
Upside
Reiterated
06/09/25
Axsome Therapeutics shows promising growth prospects with strong revenue increases and pipeline advancements. However, financial challenges, including ongoing losses and cash flow issues, weigh heavily on the overall score. The recent loan agreement and positive technical indicators provide some support, but regulatory hurdles and profitability concerns remain significant risks.
William Blair Analyst forecast on AXSM
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
06/09/25
Axsome Therapeutics' Growth Prospects Remain Strong Despite FDA Setback on AXS-14
Needham Analyst forecast on AXSM
Ami FadiaNeedham
Needham
$153$150
Buy
36.52%
Upside
Reiterated
06/09/25
Axsome Therapeutics' Strategic Response to FDA Feedback Supports Buy Rating
Oppenheimer Analyst forecast on AXSM
Jay OlsonOppenheimer
Oppenheimer
$185$183
Buy
66.56%
Upside
Reiterated
06/09/25
Oppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Wells Fargo Analyst forecast on AXSM
Cerena ChenWells Fargo
Wells Fargo
$165
Buy
50.18%
Upside
Reiterated
06/09/25
Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05
TD Cowen Analyst forecast on AXSM
Joseph ThomeTD Cowen
TD Cowen
$190
Buy
72.93%
Upside
Reiterated
06/09/25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Harrow Health (HROW)
Morgan Stanley Analyst forecast on AXSM
Vikram PurohitMorgan Stanley
Morgan Stanley
$190
Buy
72.93%
Upside
Reiterated
06/06/25
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), Apellis Pharmaceuticals (NASDAQ: APLS) and Bio-Rad Laboratories (NYSE: BIO)
H.C. Wainwright Analyst forecast on AXSM
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$180
Buy
63.83%
Upside
Reiterated
06/02/25
Strategic Settlements and Market Opportunities Bolster Axsome Therapeutics' Buy Rating
Mizuho Securities Analyst forecast on AXSM
Graig SuvannavejhMizuho Securities
Mizuho Securities
$210
Buy
91.13%
Upside
Reiterated
05/30/25
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason GerberryBank of America Securities
Bank of America Securities
$176
Buy
60.19%
Upside
Reiterated
05/14/25
Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities
Truist Financial Analyst forecast on AXSM
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/06/25
Truist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
Robert W. Baird Analyst forecast on AXSM
Joel BeattyRobert W. Baird
Robert W. Baird
$160$162
Buy
47.45%
Upside
Reiterated
05/06/25
Axsome Therapeutics price target raised to $162 from $160 at BairdAxsome Therapeutics price target raised to $162 from $160 at Baird
Guggenheim Analyst forecast on AXSM
Yatin SunejaGuggenheim
Guggenheim
$195
Buy
77.48%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Leerink Partners Analyst forecast on AXSM
Marc GoodmanLeerink Partners
Leerink Partners
$150
Buy
36.52%
Upside
Reiterated
05/05/25
Strong Buy Rating for Axsome Therapeutics Driven by Product Performance and Pipeline Progress
RBC Capital Analyst forecast on AXSM
Leonid TimashevRBC Capital
RBC Capital
$193
Buy
75.66%
Upside
Reiterated
05/05/25
Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on AXSM
TipRanks AITipRanks
Not Ranked
TipRanks
$113
Hold
2.85%
Upside
Reiterated
06/09/25
Axsome Therapeutics shows promising growth prospects with strong revenue increases and pipeline advancements. However, financial challenges, including ongoing losses and cash flow issues, weigh heavily on the overall score. The recent loan agreement and positive technical indicators provide some support, but regulatory hurdles and profitability concerns remain significant risks.
William Blair Analyst forecast on AXSM
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
06/09/25
Axsome Therapeutics' Growth Prospects Remain Strong Despite FDA Setback on AXS-14
Needham Analyst forecast on AXSM
Ami FadiaNeedham
Needham
$153$150
Buy
36.52%
Upside
Reiterated
06/09/25
Axsome Therapeutics' Strategic Response to FDA Feedback Supports Buy Rating
Oppenheimer Analyst forecast on AXSM
Jay OlsonOppenheimer
Oppenheimer
$185$183
Buy
66.56%
Upside
Reiterated
06/09/25
Oppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Wells Fargo Analyst forecast on AXSM
Cerena ChenWells Fargo
Wells Fargo
$165
Buy
50.18%
Upside
Reiterated
06/09/25
Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05
TD Cowen Analyst forecast on AXSM
Joseph ThomeTD Cowen
TD Cowen
$190
Buy
72.93%
Upside
Reiterated
06/09/25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Harrow Health (HROW)
Morgan Stanley Analyst forecast on AXSM
Vikram PurohitMorgan Stanley
Morgan Stanley
$190
Buy
72.93%
Upside
Reiterated
06/06/25
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), Apellis Pharmaceuticals (NASDAQ: APLS) and Bio-Rad Laboratories (NYSE: BIO)
H.C. Wainwright Analyst forecast on AXSM
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$180
Buy
63.83%
Upside
Reiterated
06/02/25
Strategic Settlements and Market Opportunities Bolster Axsome Therapeutics' Buy Rating
Mizuho Securities Analyst forecast on AXSM
Graig SuvannavejhMizuho Securities
Mizuho Securities
$210
Buy
91.13%
Upside
Reiterated
05/30/25
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)
Bank of America Securities Analyst forecast on AXSM
Jason GerberryBank of America Securities
Bank of America Securities
$176
Buy
60.19%
Upside
Reiterated
05/14/25
Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities
Truist Financial Analyst forecast on AXSM
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/06/25
Truist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
Robert W. Baird Analyst forecast on AXSM
Joel BeattyRobert W. Baird
Robert W. Baird
$160$162
Buy
47.45%
Upside
Reiterated
05/06/25
Axsome Therapeutics price target raised to $162 from $160 at BairdAxsome Therapeutics price target raised to $162 from $160 at Baird
Guggenheim Analyst forecast on AXSM
Yatin SunejaGuggenheim
Guggenheim
$195
Buy
77.48%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Leerink Partners Analyst forecast on AXSM
Marc GoodmanLeerink Partners
Leerink Partners
$150
Buy
36.52%
Upside
Reiterated
05/05/25
Strong Buy Rating for Axsome Therapeutics Driven by Product Performance and Pipeline Progress
RBC Capital Analyst forecast on AXSM
Leonid TimashevRBC Capital
RBC Capital
$193
Buy
75.66%
Upside
Reiterated
05/05/25
Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

1 Month
xxx
Success Rate
12/19 ratings generated profit
63%
Average Return
+0.01%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +0.01% per trade.
3 Months
xxx
Success Rate
12/17 ratings generated profit
71%
Average Return
+8.05%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +8.05% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
15/17 ratings generated profit
88%
Average Return
+22.42%
reiterated a buy rating 9 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +22.42% per trade.
2 Years
xxx
Success Rate
30/32 ratings generated profit
94%
Average Return
+57.86%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +57.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
19
20
24
33
33
Buy
56
61
53
29
15
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
75
81
77
62
48
In the current month, AXSM has received 48 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 178.00.
Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$1.05 with a range of -$1.67 to -$0.46. The previous quarter’s EPS was -$1.22. AXSM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.48% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s earnings estimate for AXSM is -$1.05 with a range of -$1.67 to -$0.46. The previous quarter’s EPS was -$1.22. AXSM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.48% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $140.06M with a range of $135.11M to $148.10M. The previous quarter’s sales results were $121.46M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 49.57% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s sales forecast for AXSM is $140.06M with a range of $135.11M to $148.10M. The previous quarter’s sales results were $121.46M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 49.57% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 178.00.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 62.01% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s price target?
            The average price target for Axsome Therapeutics Inc is 178.00. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $210.00 ,the lowest forecast is $148.00. The average price target represents 62.01% Increase from the current price of $109.87.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis